Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

MyoKardia and Sanofi part ways in collaboration
January 2019
by DDNews Staff  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

SOUTH SAN FRANCISCO, Calif.—MyoKardia Inc, a clinical-stage biopharmaceutical company focused on precision medicine for the treatment of cardiovascular diseases, recently announced it had regained worldwide rights to all programs covered under its license and collaboration agreement with Sanofi. The collaboration will not be extended beyond the initial research term, which ended on Dec. 31, 2018, and will conclude in its entirety effective April 1, 2019. As a result, MyoKardia now has global rights to all programs in its portfolio, including lead clinical-stage candidates, mavacamten and MYK-491.
 
“We are grateful for Sanofi’s support over the past four years in what was a highly productive relationship. Since entering into the collaboration, MyoKardia has become a leading research and development organization with a robust pipeline of targeted cardiovascular therapeutics,” said Tassos Gianakakos, MyoKardia’s CEO. “Regaining worldwide rights enables us to capture the full value of the data being generated in the next 12 to 24 months as we prepare for the potential registration of mavacamten in obstructive hypertrophic cardiomyopathy and obtain proof-of-concept for MYK-491 in patients with dilated cardiomyopathy. Importantly, consolidated control over our entire portfolio allows us to make decisions about how we advance each of our therapeutic candidates in alignment with our precision medicine approach.”
 
MyoKardia and Sanofi initiated their collaboration in 2014 to advance up to three programs through discovery and into clinical development for the treatment of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).
 
Over the course of the collaboration, MyoKardia received approximately $230 million in funding from Sanofi and has advanced mavacamten from preclinical development into a late-stage pivotal study for the treatment of HCM, and MYK-491 from discovery to a Phase 2 proof-of-concept study in patients with DCM. During the period leading up to the end of the research term, it was important for MyoKardia to maintain 100 percent of the U.S. commercial rights for mavacamten in HCM as well as additional rights in expanded indications. Sanofi subsequently provided MyoKardia with notification of its decision to conclude the collaboration in conjunction with the end of the research term.
 
 
Code: E011929

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.